Novye podkhody k diagnostike i lecheniyu neyroendokrinnykh opukholey


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article presents characteristics of highly differentiated neuroendocrine tumors (NETs) with a description of the clinical symptoms and syndromes, depending on the functional activity of the tumor. The aspects of the differential diagnosis for various types of NETs are suggested. The role of somatostatin analogues in the treatment of systemic NEO as a major anti-secretory agents and drugs with proven anti-tumor activity is demonstrated. The information on the efficacy and safety of prolonged somatostatin analogue Somatuline® Autogel® 120 mg in the treatment of patients with highly differentiated gastroenteropancreatic NETs according to the results of CLARINET and OLE studies is provided.

Full Text

Restricted Access

References

  1. Vinik A.I., Woltering E.A., Warner R.R., Caplin M., O'Dorisio T.M., Wiseman G.A, Coppola D., Go V.L. North American Neuroendocrine Tumor Society (NANETS). NANETS consensus guidelines for the diagnosis of neuroendocrine tumor. Pancreas. 2010;39:713-34.
  2. Caplin M.E., Buscombe J.R., Hilson A.I., Jones A.L., Watkinson A.F., Burroughs A.K. Carcinoid tumour. Lancet. 1998;352:799-805.
  3. Kaltsas G.A., Besser G.M., Grossman A.B. The diagnosis and medical management of advanced neuroendocrine tumours. Endocrinol. Rev. 2004; 25:458-511.
  4. Jensen R.T. Gastrointestinal endocrine tumours. Gastrinoma. Baillieres Clin. Gastroenterol. 1996;10:603-43
  5. Симоненко В.Б., Дулин П.А., Маканин М.А. Нейроэндокринные опухоли. М., 2010. С. 111, 121, 138-39.
  6. Soga J., Yakuwa Y. Vipoma/diarrheogenic. J. Exp. Clin. Cancer Res. 1998;17:389-400.
  7. Chastain M.A. The glucagonoma syndrome: a review of its features and discussion of new perspectives. Am. J. Med. Sci. 2001;321:306-20.
  8. Soga J., Yakuwa Y. Somatostatinoma/inhibitory syndrome: a statistical evaluation of 241 reported cases. Syndrome: a statistical evaluation of 173 reported cases (as compared to other pancreatic endocrinomas). J. Exp. Clin. Cancer Res. 1999;18:13-22.
  9. Lesurtel M., Soll C., Graf R., Clavien P.A. Role of serotonin in the gepato-gastrointestinal tract: an old molecule for new perspectives. Cell. Moll. Life Sci. 2008;65:940-52.
  10. Пальцев М.А., Кветной И.М. Руководство по нейроиммуноэндокринологии. М., 2008. С. 79.
  11. Kulke M.H., Mayer R.J. Carcinoid tumours. N. Engl. J. Med. 1999;340:858-68.
  12. Woodart P.K., Feldman J.M., Paine S.S., Baker M.E. Midgaut carcinoid tumors: CT findings and biochemical profiles. J. Comput. Assist. Tomogr. 1995;19:400-05.
  13. Pellikka P.A., Tajik A.J., Khandheria B.K., Seward J.B., Callahan J.A., Pitot H.C., Kvols L.K. Carcinoid heart desease: clinical and echocardiografic spectrum in 74 patients. Circulation. 1993; 87:1188-96.
  14. Oberg K Neuroendocrine gastrointestinal tumours-a condenced overview of diagnosis and treatment. Ann. Oncol. 1999;10(suppl 2):S3-S8.
  15. McEnlee G.P., Nagomey D.M., Kvols L.K., Moertel C.G., Grant C.S. Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery. 1990; 108(6): 1091 -96.
  16. Vogl T.J, Naguib N.N., Zangos S., Eichler K., Hedayati A., Nour-Eldin NE. Liver metastases of neuroendocrine carcinomas: interventional treatment via transarterial embolization, chemoem-bolization and thermal ablation. Eur. J. Radiol. 2009;72(3):517-28.
  17. Reichlin S. Secretion of somatostatin and its physiologic function. J. Lab. Clin. Med. 1987; 109:320-26.
  18. Longnecker S.M. Somatostatin and octreotide: literature review and description of therapeutic activity in pancreatic neoplasia. Drug Intelligence Clin. Pharm. 1988;22:99-106.
  19. Reubi J., Wasser B., Schaer J., et al. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur. J. Nucl. Med. 2001;28:836-46.
  20. Oberg K.E.The management of neuroendocrine tumours: current and future medical therapy options. Clin. Oncol. 2012;24(4):282-93.
  21. Yao J.C., Hassan M., Phan A., Dagohoy C., Leary C., Mares J.E., Abdalla E.K., Fleming J.B., Vauthey J.N., Rashid A., Evans D.B. One hundred years after «carcinoid»: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J. Clin. Oncol. 2008;26:3063-72.
  22. Grozinsky-Glasberg S., Shimon I., Korbonits M., Grossman A.B. Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mecha -nisms. Endocr. Relat. Cancer. 2008;15(3):701-20.
  23. Rinke A., Miller H.H., Schade-Brittinger C., Klose K.J., Barth P., Wied M., Mayer C., Aminossadati B., Pape U.F., Blaker M., Harder J., Arnold C., Gress T., Arnold R.; PROMID Study Group. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROM ID Study Group. J. Clin. Oncol. 2009;27(28):4656-63.
  24. Caplin M.A., Ruszniewski P.B., Pavel M.C., Cwikla J.D., Phan A.E., Raderer M.F. l. Progression-Free Survival (PFS) and Tumor Growth with Lanreotide Autogel (LAN) in Patients (Pts) with Enteropancreatic NETs: Result CLARINET, a Randomized, Double-Blind, Placebo (Pbo)-Controlled. In: Abstractsbook ENETS. 2014:149.
  25. Caplin M., Pavel M., Cwikla J.B., Phan A.T., Raderer M., Sedlackova E., Cadiot G., Wolin E.M., Capdevila J., Wall L., Rindi G., Langley A., Martinez S., Blumberg J., Ruszniewski P.; CLARINET Investigators. Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors. N. Engl. J. Med. 2014;371(3):224-33.
  26. Rinke A., Muller H.H., Schade-Brittinger C., Klose K.J., Barth P., Wied M., Mayer C., Aminossadati B., Pape U.F., Blaker M., Harder J., Arnold C., Gress T., Arnold R.; PROMID Study Group. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J. Clin. Oncol. 2009;27:4656-63.
  27. Bevan J.S., Newell-Price J., Wass J.A., Atkin S.L., Bouloux P. M., Chapman J., et al. Home administration of lanreotide Autogel by patients with acromegaly, or their partners, is safe and effective. Clin. Endocrinol. (Oxf). 2008; 68(3):343-49.
  28. Johanson V, Wilson В., Abrahamsson A., Jianu C., Calissendorff'J., Wall N., Gronbek H., Florholmen J., Ohberg A., Granberg D. Randomized crossover study in patients with neuroendocrine tumors to assess patient preference for lanreotide Autogel given by either self/partner or a health care professional. Patient Prefer. Adherence. 2012;6:703-10.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2015 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies